Comment Period Open for FDA Draft Guidance on Osteoporosis Treatments; Plus FDA Rejects Abuse-Deterrent Apadaz Michele B. Kaufman, PharmD, BCGP | June 22, 2016 Page: 1 2 | Single Page Share: